The First Interchangeable US-Approved Biosimilar Product- Glargine.

Speciality: Endocrinology


Speaker:

DR. Shalini Jaggi | MBBS, Fellowship in Diabetology (Chennai), PG Diploma in Diabetes (Cardiff, UK), PG Diploma in Endocrinology (UK), ADHA (Chennai), FRSSDI, FACE (USA), FRCP (Edinburgh), FRCP (Glasgow), FRCP (London), Fellowship in Diabetology, Consultant Director & Diabetologist at Lifecare Diabetes Centre

Description:

A warm welcome to all the medical practitioners in this interesting session on the first interchangeable US-approved biosimilar product- Glargine.

Insulin is a hormone secreted from the pancreas that helps blood sugar to enter the body's cells so it can be used for energy. Insulin also signals the liver to store blood sugar for later use. It is one of the important components that help in controlling diabetes in patients.

Biosimilar insulins are manufactured in living organisms (e.g., yeast and bacteria) to produce large quantities of the product, which limits the ability to manufacture exact replicas of original biological medications. Insulin glargine is a synthetic version of human insulin that is FDA-approved to treat adults and children. It is long-acting with the ability to control sugar all day long.

Insulin glargine, a product of Biocon, is the first interchangeable US FDA-approved biosimilar product, a long-acting, synthetic version of human insulin that works by replacing the normally produced insulin and by helping sugar to move out from the blood into other body tissues where it is used in the form of energy. 

Therefore, listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
 


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer during young adulthood carries long-term mental toll, study finds

2.

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

3.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

4.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

5.

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot